ArticleIranian journal of pharmaceutical research : IJPR
Yishen Xiaoke Formula Delays Renal Fibrosis in Rats with Diabetic Nephropathy by Suppressing the Transforming Growth Factor-Beta 1/Notch Signalling Pathway.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yishen Xiaoke Formula (YSXKF), derived from the classical prescription Yuquan San, has been used clinically to treat diabetic nephropathy (DN) in patients with qi-yin deficiency syndrome. Objectives: This study investigated whether YSXKF delays renal fibrosis progression in DN rats by regulating the transforming growth factor-beta 1 (TGF-β1)/Notch signalling pathway. Methods: Seventy-five male Sprague Dawley rats were included and randomly assigned to a control cohort (15 rats) or a model cohort (60 rats). DN was induced by unilateral nephrectomy, a high-fat/high-sucrose diet, and streptozotocin injection. DN rats were treated with YSXKF, irbesartan, or YSXKF combined with TGF-β1 activation for 8 weeks. After 8 weeks of intervention, 24-h urinary total protein (24-h UTP), circulating TGF-β1 levels, fasting blood glucose (FBG), and serum creatinine (Scr) were evaluated. Masson staining was performed to assess renal pathological changes, and quantitative reverse transcription polymerase chain reaction and immunohistochemistry were conducted to assess the levels of TGF-β1, Jagged1, and Hes1 in renal tissue. Results: Compared with DN rats, YSXKF treatment significantly reduced 24-h UTP excretion, circulating TGF-β1 levels, FBG, and Scr. Histological analysis revealed attenuated glomerulosclerosis and interstitial fibrosis. YSXKF decreased renal mRNA and protein expression of TGF-β1, Jagged1, and Hes1. Activation of TGF-β1 markedly reversed these protective effects and restored Notch pathway activation. Conclusions: YSXKF delays renal fibrosis progression in DN rats by downregulating TGF-β1 expression and inhibiting Jagged1/Hes1 activation in the Notch signaling pathway, thereby reducing extracellular matrix deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.